30-Second Takeaway
- Natural-cycle FET appears safer than HRT-FET for obstetric outcomes in singleton pregnancies.
- Low-dose aspirin may mitigate heat-associated preterm birth risk in nulliparas.
- Most pregnancy-specific alcohol policies do not clearly improve maternal-infant outcomes and can harm.
Week ending May 9, 2026
Selected recent evidence with practical implications for obstetrics and reproductive care
Compassionate trial care promoted buprenorphine uptake among pregnant and postpartum people of color
In qualitative interviews of 17 pregnant and postpartum participants of color from the MOMs buprenorphine trial, participants reported nonjudgmental, non-discriminatory care across seven sites. Frequent, personalized, integrated encounters and emotional support helped overcome prior stigma and facilitated medication initiation and adherence. Trust in the care team and transparent communication reduced concerns about taking an investigational drug during pregnancy. Findings apply to trial-enrolled pregnant and postpartum people of color and highlight care processes that may improve OUD treatment engagement.
Most pregnancy-specific alcohol policies showed mixed or harmful associations among Medicaid births
In a retrospective cohort of 10,329,565 Medicaid maternal-infant dyads (2000–2019), most pregnancy-specific alcohol policies had no clear net benefit. Only Reporting Requirements for Assessment/Treatment was consistently associated with improved outcomes (aORs down to 0.86 for SMM). Reporting Requirements for Child Protective Services correlated with worse infant outcomes (aORs up to 1.19 for injury), with other policies showing offsetting harms and benefits. Results apply to Medicaid-covered births and suggest policymakers should not assume uniform benefit from pregnancy-specific alcohol statutes.
Low-dose aspirin attenuated heat-associated preterm birth in a randomized trial subgroup analysis
Secondary analysis of the ASPIRIN trial (n=11,558 nulliparas) found each 1°C rise in humid heat increased preterm birth odds by 5% overall (AOR 1.05). The heat-associated increased preterm risk was present in placebo recipients (AOR 1.07) but not in aspirin recipients (AOR 1.03). Preterm births were fewer with aspirin (668/5787) than placebo (754/5771), suggesting aspirin may mitigate heat vulnerability. This is a secondary analysis across diverse low-resource settings; interpret as hypothesis-supporting rather than definitive practice-changing evidence.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.